Site Advocacy Group Initiative Launched for Clinical Research
- By BSTQ Staff
The Society for Clinical Research Sites (SCRS) and TransCelerate BioPharma Inc. have launched the Site Advocacy Group (SAG), an initiative that enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools and technologies. SCRS members representing a broad spectrum of site professionals and clinical research sites will partner with TransCelerate workstream members to exchange feedback on various topics. In return, industry leaders will share with the sites their key priorities and initiatives to elevate the industry. Outcomes from the SAG initiative will help to inform collaborative initiatives within the industry aimed at enhancing safety, efficiency and innovations. Results from the SAG initiative will also be poised to enhance operational and business performance for the sites.
TransCelerate is a nonprofit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and improving patient safety, with the goal of delivering more high-quality medicines to patients. “This SAG program will provide TransCelerate workstreams direct access to the voice of investigative sites around the world, gather timely input and feedback on projects and further optimize the impact we can make on clinical trials efficiency,” said Dalvir Gill, PhD, chief executive officer of TransCelerate. More information can be obtained from SCRS at myscrs.org.
